- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00034333
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients With Unresectable Hepatocellular Carcinoma
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon. When DOX is added to MTCs, DOX attaches to the carbon part of the MTCs. MTC-DOX is directed to and deposited in the area of a tumor, where it is thought that it then "leaks" through the blood vessel walls. Once in the surrounding tissues, it is thought that Doxorubicin becomes "free from" the magnetic beads and will then be able to act against the tumor cells. The iron component of the particle has magnetic properties, making it possible to direct MTC-DOX to specific tumor sites in the liver by placing a magnet on the body surface. It is hoped that MTC-DOX used with the magnet may target the chemotherapy directly to liver tumors and provide a treatment to patients with liver cancer.
To be sure of the effect of MTC-DOX on liver cancer, it will be compared to the effect of Doxorubicin given through the vein.
The study treatments will be administered every three weeks, (which is considered a study treatment cycle), until you complete six treatment cycles, the tumor grows, disappears, or you experience a side effect, which may cause you to leave the study. Follow-up visits will occur on Days 3, 10, and 21 following treatment in the first cycle and Days 7 and 21 for the remaining cycles, and also 60 days after you receive your last treatment cycle.
Therefore, the purpose of this Phase 2/3 study is to evaluate safety, tolerance, and efficacy (survival time) of an MTC-DOX dosing strategy where the DOX dose is determined by tumor size
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- Landeskrankenhaus Graz University Hospital
-
Vienna, Austria
- University Hospital Vienna
-
-
-
-
-
Cologne, Germany, 50924
- University Hospital Cologne
-
Frankfurt, Germany
- University Hospital Am Main
-
-
-
-
-
Pokfulam, Hong Kong
- Queen Mary Hospital, University of Hong Kong
-
Shatin, N.T., Hong Kong
- Chinese Universtiy of Hong Kong
-
-
-
-
-
Moscow, Russian Federation, 115478
- N.N. Blokhin Cancer Research Center RAMS
-
-
St. Petersburg
-
Pesochny, St. Petersburg, Russian Federation, 197758
- Central Research Institute of Roentgenology and Radiology
-
-
-
-
-
Bangkok, Thailand, 10700
- Siriraj Hospital, Mahidol University
-
Bangkok, Thailand, 10330
- Chulalongkorn University Hospital
-
Bangkok, Thailand
- National Cancer Institute
-
Chiang Mai, Thailand
- Chiang Mai University
-
Khon Kaen, Thailand, 40002
- Khon Kaen Universtiy
-
-
-
-
-
Kiev, Ukraine, 03022
- Institute of Oncology AMS of Ukraine
-
-
-
-
Birmingham
-
Edgbaston, Birmingham, United Kingdom, B152TH
- Queen Elizabeth Hospital
-
-
England
-
Leicester, England, United Kingdom
- Leicester Royal Infirmary
-
London, England, United Kingdom
- St. George's Hospital
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom
- Edinburgh Royal Infirmary
-
-
-
-
California
-
Long Beach, California, United States, 90822
- Long Beach VA Medical Center
-
San Francisco, California, United States, 94121
- VAMC San Francisco and Comprehensive Cancer Ctr.
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Univ. Med. School
-
-
New York
-
New York, New York, United States, 10021
- Weill Medical College of Cornell University
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Univ. of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny-Singer Research Institute
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch
-
Temple, Texas, United States, 76508
- Scott & White Mem. Hosp. & Clinic
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- McGuire DVAMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients may be enrolled into this protocol only if all of the following inclusion criteria are met:
- Unresectable hepatocellular carcinoma diagnosed by CT scan and meets the criteria described in Section 23.
- Total combined cross-sectional area of all hepatic tumors as determined by CT scan is between 4 and 200 cm2.
- Center of the tumor(s) mass must be </= 14 cm from the anterior lateral abdominal wall as determined by cross-sectional imaging at baseline. This is required for optimal placement of the magnet. If more than one tumor mass is present, all of the tumor masses must meet this criterion.
- Is ambulatory with a Karnofsky performance status score > 60 and an estimated life expectancy of > 3 months.
- Is judged by the investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to allow follow-up.
- Have the ability to give informed written consent prior to initiation of therapy.
- If female and of childbearing potential,must have a negative beta-HCG prior to receiving treatment.
- Must agree to use an effective method of contraception
Patients will be excluded from enrollment if any of the following apply:
- Has a history of cancer other than hepatocellular (excluding resected basal cell carcinoma; or curatively resected stage 1 or less cervical cancer if disease free for 5 years or more).
- Has had prior local radiation therapy within the last 4 weeks, mediastinal radiation therapy within the last 3 months, or chemotherapy within the last 4 weeks.
- Diffuse hepatocellular carcinoma or disease that precludes delivery of the drug to the tumor via a vessel that feeds the tumor.
- Has another active medical condition(s) or organ disease(s) that may either compromise patient safety or interfere with the safety and/or outcome (e.g., survival) evaluation of the study drugs. While this exclusion is not limited to the following abnormalities, if any of the following laboratory abnormalities are present, the patient should be excluded:
WBC < 2,000 /uL Platelets < 50,000/uL Hemoglobin < 8.0 gm/dL Total bilirubin > 3.0 mg/dL ALT or AST >/= 5 x upper limit of normal Serum Creatinine >2.0 mg/dL INR >/= 1.5
- Has cardiac dysfunction with a left ventricular ejection fraction < 40%.
- Has clinically significant pulmonary impairment
- Plans concomitant chemotherapy, radiation therapy, hormonal and/or biological treatment for cancer including immunotherapy while on study.
- Has an indwelling cardiac pacemaker, cerebral aneurysm clips, or any other indwelling device or appliance that could be adversely affected by the use of the external magnet.
- Has documented evidence of hemachromatosis or hemosiderosis.
- Has CT or ultrasound evidence of portal vein invasion or thrombosis.
- Prior orthotopic hepatic transplant.
- Has received previous treatment with doxorubicin, idarubicin, and/or other anthracyclines or anthracenes.
- Has a known allergy to doxorubicin, MTC-DOX or any of their components.
- Has been treated with any investigational drug, investigational biologic, or investigational therapeutic device within 30 days of initiating study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Joy Koda, Ph.D., FeRx
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MTC-DOX-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Hepatocellular
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on MTC-DOX for Injection
-
FeRxUnknown
-
FeRxCompletedMelanoma | Sarcoma | Stomach Neoplasms | Gastrointestinal Neoplasms | Breast Neoplasms | Lung Neoplasms | Liver Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Metastases, Neoplasm | CholangiocarcinomaUnited States, Germany
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States
-
Aro BiotherapeuticsRecruiting
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, Taiwan, Georgia, United States
-
AstraZenecaCompletedChronic PainGermany, Sweden, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Reunion Neuroscience IncNot yet recruitingPostpartum Depression